ERBB2 and triple-negative breast carcinoma: It is a heterogeneous disease characterized by different molecular profiles and clinicopathological features, and is classified into various subtypes based on receptor status, including receptor-positive (luminal A, luminal B, normal-like, and human epidermal growth factor receptor 2-positive, HER-2) and receptor-negative (triple-negative breast cancer, TNBC) subtypes [2].